vs

Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Emergent BioSolutions Inc. (EBS). Click either name above to swap in a different company.

ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $148.7M, roughly 1.6× Emergent BioSolutions Inc.). On growth, ASTRONICS CORP posted the faster year-over-year revenue change (15.1% vs -23.6%). Emergent BioSolutions Inc. produced more free cash flow last quarter ($73.8M vs $15.8M). Over the past eight quarters, ASTRONICS CORP's revenue compounded faster (13.9% CAGR vs -29.6%).

Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

ATRO vs EBS — Head-to-Head

Bigger by revenue
ATRO
ATRO
1.6× larger
ATRO
$240.1M
$148.7M
EBS
Growing faster (revenue YoY)
ATRO
ATRO
+38.7% gap
ATRO
15.1%
-23.6%
EBS
More free cash flow
EBS
EBS
$58.0M more FCF
EBS
$73.8M
$15.8M
ATRO
Faster 2-yr revenue CAGR
ATRO
ATRO
Annualised
ATRO
13.9%
-29.6%
EBS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATRO
ATRO
EBS
EBS
Revenue
$240.1M
$148.7M
Net Profit
$-54.6M
Gross Margin
33.3%
42.9%
Operating Margin
14.8%
-18.8%
Net Margin
-36.7%
Revenue YoY
15.1%
-23.6%
Net Profit YoY
-74.4%
EPS (diluted)
$0.82
$-0.95

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRO
ATRO
EBS
EBS
Q4 25
$240.1M
$148.7M
Q3 25
$211.4M
$231.1M
Q2 25
$204.7M
$140.9M
Q1 25
$205.9M
$222.2M
Q4 24
$208.5M
$194.7M
Q3 24
$203.7M
$293.8M
Q2 24
$198.1M
$254.7M
Q1 24
$185.1M
$300.4M
Net Profit
ATRO
ATRO
EBS
EBS
Q4 25
$-54.6M
Q3 25
$-11.1M
$51.2M
Q2 25
$1.3M
$-12.0M
Q1 25
$9.5M
$68.0M
Q4 24
$-31.3M
Q3 24
$-11.7M
$114.8M
Q2 24
$1.5M
$-283.1M
Q1 24
$-3.2M
$9.0M
Gross Margin
ATRO
ATRO
EBS
EBS
Q4 25
33.3%
42.9%
Q3 25
30.5%
62.8%
Q2 25
25.8%
52.5%
Q1 25
29.5%
60.2%
Q4 24
29.8%
39.4%
Q3 24
27.1%
54.9%
Q2 24
28.0%
-18.8%
Q1 24
25.7%
49.2%
Operating Margin
ATRO
ATRO
EBS
EBS
Q4 25
14.8%
-18.8%
Q3 25
10.9%
33.1%
Q2 25
2.3%
1.1%
Q1 25
6.4%
22.5%
Q4 24
4.3%
-4.9%
Q3 24
4.1%
22.0%
Q2 24
3.8%
-79.9%
Q1 24
0.9%
13.2%
Net Margin
ATRO
ATRO
EBS
EBS
Q4 25
-36.7%
Q3 25
-5.2%
22.2%
Q2 25
0.6%
-8.5%
Q1 25
4.6%
30.6%
Q4 24
-16.1%
Q3 24
-5.8%
39.1%
Q2 24
0.8%
-111.2%
Q1 24
-1.7%
3.0%
EPS (diluted)
ATRO
ATRO
EBS
EBS
Q4 25
$0.82
$-0.95
Q3 25
$-0.31
$0.91
Q2 25
$0.04
$-0.22
Q1 25
$0.26
$1.19
Q4 24
$-0.07
$-0.45
Q3 24
$-0.34
$2.06
Q2 24
$0.04
$-5.38
Q1 24
$-0.09
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRO
ATRO
EBS
EBS
Cash + ST InvestmentsLiquidity on hand
$18.2M
$205.4M
Total DebtLower is stronger
$589.7M
Stockholders' EquityBook value
$140.1M
$522.6M
Total Assets
$706.7M
$1.3B
Debt / EquityLower = less leverage
1.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRO
ATRO
EBS
EBS
Q4 25
$18.2M
$205.4M
Q3 25
$13.5M
$245.5M
Q2 25
$13.5M
$267.3M
Q1 25
$24.8M
$149.1M
Q4 24
$9.3M
$99.5M
Q3 24
$5.2M
$149.9M
Q2 24
$2.9M
$69.7M
Q1 24
$5.3M
$78.5M
Total Debt
ATRO
ATRO
EBS
EBS
Q4 25
$589.7M
Q3 25
$693.1M
Q2 25
$700.0M
Q1 25
$700.0M
Q4 24
$700.0M
Q3 24
$700.8M
Q2 24
$863.8M
Q1 24
$909.2M
Stockholders' Equity
ATRO
ATRO
EBS
EBS
Q4 25
$140.1M
$522.6M
Q3 25
$108.9M
$582.5M
Q2 25
$271.6M
$536.2M
Q1 25
$266.8M
$552.7M
Q4 24
$256.1M
$482.8M
Q3 24
$249.2M
$508.4M
Q2 24
$257.9M
$386.3M
Q1 24
$251.7M
$663.9M
Total Assets
ATRO
ATRO
EBS
EBS
Q4 25
$706.7M
$1.3B
Q3 25
$682.2M
$1.5B
Q2 25
$646.7M
$1.4B
Q1 25
$662.2M
$1.4B
Q4 24
$648.8M
$1.4B
Q3 24
$651.6M
$1.5B
Q2 24
$644.9M
$1.5B
Q1 24
$630.0M
$1.8B
Debt / Equity
ATRO
ATRO
EBS
EBS
Q4 25
1.13×
Q3 25
1.19×
Q2 25
1.31×
Q1 25
1.27×
Q4 24
1.45×
Q3 24
1.38×
Q2 24
2.24×
Q1 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRO
ATRO
EBS
EBS
Operating Cash FlowLast quarter
$27.6M
$77.7M
Free Cash FlowOCF − Capex
$15.8M
$73.8M
FCF MarginFCF / Revenue
6.6%
49.6%
Capex IntensityCapex / Revenue
4.9%
2.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$43.1M
$156.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRO
ATRO
EBS
EBS
Q4 25
$27.6M
$77.7M
Q3 25
$34.2M
$-2.3M
Q2 25
$-7.6M
$106.4M
Q1 25
$20.6M
$-11.2M
Q4 24
$26.4M
$-79.9M
Q3 24
$8.4M
$153.7M
Q2 24
$-6.3M
$47.5M
Q1 24
$2.0M
$-62.6M
Free Cash Flow
ATRO
ATRO
EBS
EBS
Q4 25
$15.8M
$73.8M
Q3 25
$21.0M
$-5.7M
Q2 25
$-12.2M
$103.5M
Q1 25
$18.5M
$-14.8M
Q4 24
$23.2M
$-81.6M
Q3 24
$6.5M
$147.9M
Q2 24
$-8.1M
$42.9M
Q1 24
$439.0K
$-73.4M
FCF Margin
ATRO
ATRO
EBS
EBS
Q4 25
6.6%
49.6%
Q3 25
9.9%
-2.5%
Q2 25
-6.0%
73.5%
Q1 25
9.0%
-6.7%
Q4 24
11.1%
-41.9%
Q3 24
3.2%
50.3%
Q2 24
-4.1%
16.8%
Q1 24
0.2%
-24.4%
Capex Intensity
ATRO
ATRO
EBS
EBS
Q4 25
4.9%
2.6%
Q3 25
6.2%
1.5%
Q2 25
2.2%
2.1%
Q1 25
1.0%
1.6%
Q4 24
1.5%
0.9%
Q3 24
0.9%
2.0%
Q2 24
0.9%
1.8%
Q1 24
0.9%
3.6%
Cash Conversion
ATRO
ATRO
EBS
EBS
Q4 25
Q3 25
-0.04×
Q2 25
-5.81×
Q1 25
2.17×
-0.16×
Q4 24
Q3 24
1.34×
Q2 24
-4.08×
Q1 24
-6.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRO
ATRO

Product Line Electrical Power And Motion$113.8M47%
Product Line Avionics$32.0M13%
Military Aircraft$28.0M12%
General Aviation$22.3M9%
Government And Defense$20.5M9%
Product Line Systems Certification$13.2M6%
Product Line Structures$3.7M2%
Product Line Other$2.3M1%

EBS
EBS

Medical Countermeasures MCM Product$99.2M67%
Commercial Products Segment$38.4M26%
All Other Revenue$11.1M7%

Related Comparisons